Panacea Biotec Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Panacea Biotec Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 92% of Healthcare companies in India.
Cash Locked Ratio
₹13For every ₹100 of sales, ₹13 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹19 tied up three years earlier.
Less money tied up than 71% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹18Sales grew 33% in 3 years; of every extra ₹100 of sales, ₹18 became extra profit.
Higher than 52% of Healthcare companies in India.
Asset Productivity Ratio
+33% / -1%In 3 years sales changed by +33% while total assets changed by -1%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Higher than 83% of Healthcare companies in India.
Tangible Assets Ratio
96%Of every ₹100 the company owns, ₹96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 58% of Healthcare companies in India.
Tangible Net Worth Ratio
94%Of every ₹100 of net worth, ₹94 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 55% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Panacea Biotec Limited made a loss over the last year. Panacea Biotec Limited owes ₹0.34 for every ₹1 it owns. Panacea Biotec Limited made a loss in each of the last two years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossPanacea Biotec Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.29The share price is 2.29 times Panacea Biotec Limited's book value per share, lower than 79% of Healthcare companies in India.
Market cap
₹1,908 CrThe total market value of all of Panacea Biotec Limited's shares at today's price (share price × number of shares), smaller than 67% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹835 CrWhat Panacea Biotec Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹136.30Net worth divided by the number of shares. The share price of ₹311.45 is 2.3 times this, which is the P/B above.
Return on equity (ROE)
-0.9%Panacea Biotec Limited lost 0.9% of its shareholders' money over the last year, lower than 94% of Healthcare companies in India.
Owes vs Owns
0.34×Panacea Biotec Limited owes ₹0.34 for every ₹1 it owns (low), lower than 59% of Healthcare companies in India.
Dividend yield
NonePanacea Biotec Limited does not currently pay a dividend.
Revenue growth
+24%Revenue rose 24% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Profit growth
LossPanacea Biotec Limited made a loss in each of the last two years.
Profit margin
-0.9%Panacea Biotec Limited lost ₹1 for every ₹100 of revenue.
Interest cover
Not coveredPanacea Biotec Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net cashPanacea Biotec Limited held ₹112 Cr more cash than debt (net cash) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Panacea Biotec Limited: ₹1,908 Cr ÷ ₹835 Cr (31 Mar 2026) = 2.3.
What is Panacea Biotec Limited's return on equity?
Panacea Biotec Limited lost 0.9% of its shareholders' money over the last year, lower than 94% of Healthcare companies in India.
How much does Panacea Biotec Limited owe compared with what it owns?
Panacea Biotec Limited owes ₹0.34 for every ₹1 it owns (low), lower than 59% of Healthcare companies in India.
Does Panacea Biotec Limited pay a dividend?
No. Panacea Biotec Limited does not currently pay a dividend.
Is Panacea Biotec Limited's revenue growing?
Revenue rose 24% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.